Diffusion-Weighted and Macromolecular Contrast Enhanced MRI of Tumor Response to Antivascular Therapy with ZD6126

Jens Vogel-Claussen, Barjor Gimi, Dmitri Artemov and Zaver M. Bhujwalla

volume 6 | issue 9

September 2007
Pages: 1469 - 1475

We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:

Download PDF

If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.

The effects of the anti-vascular agent ZD6126 were studied in volume matched subcutaneous DU-145 human prostate cancer xenografts in SCID mice using two different MRI techniques, diffusion and vascular imaging. Diffusion weighted MRI was performed before and at 24 h, 48 h, and 72 h following a single dose of 200 mg/kg. Tumor vascular volume and permeability surface area product (PSP) were determined 24 h post antivascular therapy following an identical dose using dynamic contrast enhanced MRI of the macromolecular contrast agent albumin-gadolinium diethylenetriaminepentaacetate (albumin-GdDTPA). Consistent with the mechanism of action of ZD6126, significantly lower vascular volume was detected at 24 h whereas diffusion changes were evident at 48 h. Diffusion MRI findings correlated well with histological determination of the necrotic fraction in the tumors by 48 h. Both diffusion and vascular imaging are useful noninvasive techniques to detect response of tumors to antivascular therapy with ZD6126 in the DU-145 human prostate cancer xenograft model.

Authors

Jens Vogel-Claussen

Johns Hopkins University In Vivo Cellular And Molecular Imaging Center Program, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD

Barjor Gimi

Dmitri Artemov

Johns Hopkins University, School of Medicine; Baltimore MD USA

Zaver M. Bhujwalla